CSIMarket
 


Integrated Biopharma Inc  (INBP)
Other Ticker:  
 
 

INBP's Revenue Growth by Quarter and Year

Integrated Biopharma Inc's Revenue results by quarter and year




INBP Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter June - 12.38 13.27 17.06
III Quarter March 12.25 13.10 15.63 17.07
II Quarter December 10.52 12.25 14.59 14.26
I Quarter September 12.83 12.33 12.75 15.17
FY   35.60 50.06 56.24 63.56



INBP Revenue third quarter 2024 Y/Y Growth Comment
Integrated Biopharma Inc reported decrease in Revenue in the third quarter 2024 by -6.5% to $ 12.25 millions, from the same quarter in 2023.
The decrease in the third quarter 2024 Integrated Biopharma Inc's Revenue compares unfavorably to the Company's average Revenue rise of 22.06%.

Looking into third quarter 2024 results within Major Pharmaceutical Preparations industry 94 other companies have achieved higher Revenue growth. While Integrated Biopharma Inc' s Revenue decline of -6.5% ranks overall at the positon no. 1695 in the third quarter 2024.




INBP Revenue ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter June - -6.71 % -22.22 % 26 %
III Quarter March -6.5 % -16.19 % -8.44 % 25.24 %
II Quarter December -14.12 % -16.04 % 2.31 % 0.42 %
I Quarter September 4.06 % -3.29 % -15.95 % 32.95 %
FY   - -10.99 % -11.52 % 20.42 %

Financial Statements
Integrated Biopharma Inc's third quarter 2024 Revenue $ 12.25 millions INBP's Income Statement
Integrated Biopharma Inc's third quarter 2023 Revenue $ 13.10 millions Quarterly INBP's Income Statement
New: More INBP's historic Revenue Growth >>


INBP Revenue (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter June - -5.5 % -15.1 % -0.06 %
III Quarter March 16.43 % 6.94 % 7.13 % 19.71 %
II Quarter December -18 % -0.65 % 14.43 % -6 %
I Quarter September 3.63 % -7.08 % -25.26 % 12.04 %
FY (Year on Year)   - -10.99 % -11.52 % 20.42 %




Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #95
Healthcare Sector #251
Overall #1695

Revenue Y/Y Growth Statistics
High Average Low
346.88 % 22.06 % -15.14 %
(Sep. 30, 2015)   (Mar 31 2023)
Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #95
Healthcare Sector #251
Overall #1695
Revenue Y/Y Growth Statistics
High Average Low
346.88 % 22.06 % -15.14 %
(Sep. 30, 2015)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Integrated Biopharma Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
24.47 % 1.29 % -25.25 %
(Dec 31 2019)  


INBP's III. Quarter Q/Q Revenue Comment
Integrated Biopharma Inc achieved in the III. Quarter 2024 above company average sequential Revenue jump of 16.43%, to $ 12.25 millions, from $10.52 millions in the second quarter.
Major Pharmaceutical Preparations company is undergoing a remarkable growth, with claiming better then regular increase, and also improving pace.

Within Major Pharmaceutical Preparations industry 21 other companies have achieved higher Revenue quarter on quarter growth. While Integrated Biopharma Inc's Revenue growth quarter on quarter, overall rank is 280.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #22
Healthcare Sector #49
Overall #280
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #22
Healthcare Sector #49
Overall #280
Revenue Q/Q Growth Statistics
High Average Low
24.47 % 1.29 % -25.25 %
(Dec 31 2019)  


INBP's III. Quarter Q/Q Revenue Comment
Integrated Biopharma Inc achieved in the III. Quarter 2024 above company average sequential Revenue jump of 16.43%, to $ 12.25 millions, from $10.52 millions in the second quarter.
Integrated Biopharma Inc is going from strength to strength, with reporting better then normal gain, and additionally accelerating speed, Unai Serrano, a business expert added.

Within Major Pharmaceutical Preparations industry 21 other companies have achieved higher Revenue quarter on quarter growth. While Integrated Biopharma Inc's Revenue growth quarter on quarter, overall rank is 280.


Integrated Biopharma Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 47.98 $ 48.83 $ 50.57 $ 50.06 $ 50.95
Y / Y Revenue Growth (TTM) -5.81 % -8.69 % -9.41 % -11 % -15.14 %
Year on Year Revenue Growth Overall Ranking # 2089 # 422 # 2346 # 3057 # 2277
Seqeuential Revenue Change (TTM) -1.74 % -3.43 % 1.01 % -1.74 % -4.74 %
Seq. Revenue Growth (TTM) Overall Ranking # 1695 # 356 # 1949 # 2857 # 2408




Cumulative Revenue growth Comment
Integrated Biopharma Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2023. If the fiscal year would end in Mar 31 2024, Integrated Biopharma Inc's annual Revenue decline would be -5.81% year on year to $48 millions.

In the Healthcare sector 289 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 422 to 2089.

Revenue TTM Q/Q Growth Statistics
High Average Low
346.88 %
22.06 %
-15.14 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 95
Healthcare Sector # 290
Overall # 2089

Revenue TTM Y/Y Growth Statistics
High Average Low
346.88 %
22.06 %
-15.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 95
Sector # 251
S&P 500 # 1695
Cumulative Revenue growth Comment
Integrated Biopharma Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2023. If the fiscal year would end in Mar 31 2024, Integrated Biopharma Inc's annual Revenue fall would be -5.81% year on year to $48 millions.

In the Healthcare sector 289 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 422 to 2089.

Revenue TTM Q/Q Growth Statistics
High Average Low
346.88 %
22.06 %
-15.14 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 95
Healthcare Sector # 290
Overall # 2089

Revenue TTM Y/Y Growth Statistics
High Average Low
346.88 %
22.06 %
-15.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 95
Sector # 251
S&P 500 # 1695




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
INBP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for INBP's Competitors
Revenue Growth for Integrated Biopharma Inc's Suppliers
Revenue Growth for INBP's Customers

You may also want to know
INBP's Annual Growth Rates INBP's Profitability Ratios INBP's Asset Turnover Ratio INBP's Dividend Growth
INBP's Roe INBP's Valuation Ratios INBP's Financial Strength Ratios INBP's Dividend Payout Ratio
INBP's Roa INBP's Inventory Turnover Ratio INBP's Growth Rates INBP's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Collegium Pharmaceutical inc -0.21%$ -0.215 millions
Mettler Toledo International Inc-0.30%$ -0.300 millions
3m Company-0.35%$ -0.349 millions
Icu Medical Inc-0.42%$ -0.423 millions
Lifeloc Technologies Inc -0.51%$ -0.513 millions
Regeneron Pharmaceuticals Inc -0.54%$ -0.541 millions
Envista Holdings Corporation-0.62%$ -0.622 millions
Orgenesis Inc -0.70%$ -0.704 millions
Vyne Therapeutics Inc -1.01%$ -1.010 millions
Ge Healthcare Technologies Inc -1.50%$ -1.502 millions
Baxter International Inc -1.56%$ -1.562 millions
Y mabs Therapeutics inc -1.58%$ -1.580 millions
Pacific Biosciences Of California Inc -1.59%$ -1.589 millions
Cartesian Therapeutics Inc -1.65%$ -1.650 millions
Viatris Inc -1.76%$ -1.762 millions
Ocuphire Pharma Inc -2.17%$ -2.173 millions
Vaso Corporation-2.51%$ -2.513 millions
Dentsply Sirona Inc -2.56%$ -2.556 millions
Alpha Pro Tech Ltd -2.78%$ -2.775 millions
Prestige Consumer Healthcare Inc -2.82%$ -2.817 millions
West Pharmaceutical Services Inc -2.99%$ -2.986 millions
Integra Lifesciences Holdings Corp-3.14%$ -3.144 millions
Accelerate Diagnostics Inc -3.17%$ -3.165 millions
National Research Corporation-3.18%$ -3.180 millions
Catheter Precision Inc -3.53%$ -3.529 millions
Elanco Animal Health Inc-4.14%$ -4.137 millions
Ptc Therapeutics inc -4.66%$ -4.657 millions
Foghorn Therapeutics Inc -4.88%$ -4.879 millions
Aclaris Therapeutics Inc -5.14%$ -5.142 millions
Avantor Inc -5.65%$ -5.645 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com